The success of immune checkpoint blockade adds new therapeutic category to Cancers are the most heterogenous group of diseases affecting humans. Multiple compensating pathways work to promote disease progression. Various immunotherapies have shown anticancer promise, but the their targeted nature limits the scope of their action and applicability.
CAR T-cell therapy and bispecific antibodies are two approaches that have addressed the targeting of more than one epitope, the redirecting of T lymphocytes to kill tumor cells, and the improvement of efficacy in solid tumor types. For a closer look at the design, development, and success of CAR T-cell therapy and bispecific antibodies, a panel of experts come together to discuss their research and share insights into the potential these therapeutics hold in the fight against various tumor types.
Bruce Levine, PhD —Netter Professor in Cancer Gene Therapy, Founding Director, Clinical Cell and Vaccine Production Facility, Center for Cellular Immunotherapies Deputy Director – Technology Innovation and Assessment, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, Abramson Cancer Center, University of Pennsylvania
John H. Sampson, MD, PhD, MBA, MHSc — Robert H. and Gloria Wilkins Professor of Neurosurgery, Chair, Department of Neurosurgery, Duke University Medical Center
Luis A. Sanchez Perez, PhD — Assistant Professor, Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center